Next Article in Journal
Landscape Phage: Evolution from Phage Display to Nanobiotechnology
Next Article in Special Issue
Activity of the Chimeric Lysin ClyR against Common Gram-Positive Oral Microbes and Its Anticaries Efficacy in Rat Models
Previous Article in Journal / Special Issue
Structure of an Acinetobacter Broad-Range Prophage Endolysin Reveals a C-Terminal α-Helix with the Proposed Role in Activity against Live Bacterial Cells
Article Menu
Issue 6 (June) cover image

Export Article

Open AccessEssay
Viruses 2018, 10(6), 310; https://doi.org/10.3390/v10060310

Development of Phage Lysins as Novel Therapeutics: A Historical Perspective

Laboratory of Bacterial Pathogenesis and Immunology, The Rockefeller University, 1230 York Avenue, New York, NY 10065, USA
Received: 10 May 2018 / Revised: 31 May 2018 / Accepted: 5 June 2018 / Published: 7 June 2018
(This article belongs to the Special Issue Phage Lytic Enzymes and Their Applications)
Full-Text   |   PDF [3985 KB, uploaded 7 June 2018]   |  

Abstract

Bacteriophage lysins and related bacteriolytic enzymes are now considered among the top antibiotic alternatives for solving the mounting resistance problem. Over the past 17 years, lysins have been widely developed against Gram-positive and recently Gram-negative pathogens, and successfully tested in a variety of animal models to demonstrate their efficacy. A lysin (CF-301) directed to methicillin resistant Staphylococcus aureus (MRSA) has effectively completed phase 1 human clinical trials, showing safety in this novel therapeutic class. To validate efficacy, CF-301 is currently the first lysin to enter phase 2 human trials to treat hospitalized patients with MRSA bacteremia or endocarditis. If successful, it could be the defining moment leading to the acceptance of lysins as an alternative to small molecule antibiotics. This article is a detailed account of events leading to the first therapeutic use and ultimate development of phage-encoded lysins as novel anti-infectives. View Full-Text
Keywords: phage; lysins; endolysins; lytic enzymes; discovery; therapeutic; antibiotic resistance; alternative to antibiotics phage; lysins; endolysins; lytic enzymes; discovery; therapeutic; antibiotic resistance; alternative to antibiotics
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Fischetti, V.A. Development of Phage Lysins as Novel Therapeutics: A Historical Perspective. Viruses 2018, 10, 310.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top